Acadia Pharmaceuticals Inc
ACAD
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.71B
Close$
$-11.50
153.7% downside
Current Fair Value
153.7% downsideOvervalued by 153.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.71 Billion |
|---|---|
| Enterprise Value | $2.90 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.32 |
| Beta | 0.86 |
| Outstanding Shares | 170,517,000 |
Return
| Return on Equity | 30.10% |
|---|---|
| Return on Assets | 23.40% |
| Return on Invested Capital | 7.51% |
Valuation & Multiples
| P/E Ratio | 9.83 |
|---|---|
| PEG | -12.16 |
| Price to Sales | 3.57 |
| Price to Book Ratio | 3.06 |
| Enterprise Value to Revenue | 2.64 |
| Enterprise Value to EBIT | 29.66 |
| Enterprise Value to Net Income | 7 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$0.11
Average shareholder expectationRevenue Estimate
$277.46 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$296.63 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6809▼ 4.37% |
|---|---|
| Total Calls | 542,100▲ 99.08% |
| Total Puts | 369,100▲ 87.08% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.29%▼ 1.25% |
|---|---|
| Total Invested | $3.67B▼ 17.46% |
| Investors Holding | 353▲ 4.00% |
ESG Score
No data
About Acadia Pharmaceuticals Inc
CEO: Uli Hacksell